TZM, Great research. kudos to you. Hopefully JMP Securities can shop us around enough that we get more than one buyer interested. I don't think this will be a problem really. Yes it's bad out there in terms of finances. Some of the big pharmas have wads of cash and not much left in the pipeline. Here they get mepact which is a proven drug that may have benefits for other types of cancer. They get IDM-2101. I think those are worth together at a minimum of $150 million. That gets us to just over $5 a share. The buyer adds to their pipeline w/ little research left to be done. It's just investment to get a return on the drug. The key is IDMI getting the word spread at coming conferences and around the EU. We should be able to get 2 buyers interested. I can't see how you can't with such a promising proven drug and one such as IDM-2101 that could be a blockbuster. That alone is worth some cash IMO just b/c of how huge it could be. GLTA but I think we will get some good news this coming quarter. I don't think we will get the PPS that some had hoped for but most of us should make a reasonable return.
News 
Market Data 
Discover 
AI
